Adjuvant abemaciclib in early-stage breast cancer: hypothesis-generating safety observations from a real-world cohort study

Federico Sottotetti; Simone Figini; Giulia Gambini; Gavino Chessa; Erica Quaquarini; Raffaella Palumbo; Lorenzo Perrone; Alessandra Ferrari; Catherine Klersy; Paolo Pedrazzoli; Laura D. Locati; Angioletta Lasagna

doi:10.7573/dic.2025-7-5

Related Publications

Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer

Five years of adjuvant tamoxifen is more beneficial than 2 years in the treatment of postmenopausal women with estrogen receptor-positive, early stage, invasive breast cancer.

1996 JNCI Journal of the National Cancer I... 263 citations

Epithelial ovarian cancer

Stéphanie Lheureux , Charlie Gourley , Ignace Vergote +1 more

Epithelial ovarian cancer generally presents at an advanced stage and is the most common cause of gynaecological cancer death. Treatment requires expert multidisciplinary care. ...

2019 The Lancet 1776 citations

Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy.

John R. Penrod , Beata Korytowsky , Allison Petrilla +8 more

6582 Background: Prior real-world (RW) studies of advanced non-small cell lung cancer (adv NSCLC) have described overall survival (OS) from diagnosis (Dx) for all patients (pts)...

2014 Journal of Clinical Oncology 17 citations

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz , Chiun‐Sheng Huang , Max S. Mano +26 more

Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer...

2018 New England Journal of Medicine 2430 citations

Cancer in Low- and Middle-Income Countries: An Economic Overview

Susan Horton , Cindy L. Gauvreau

No AccessNov 2015Cancer in Low- and Middle-Income Countries: An Economic OverviewAuthors/Editors: Susan Horton and Cindy L. GauvreauSusan Horton and Cindy L. Gauvreauhttps://doi...

2015 The World Bank eBooks 84 citations

Publication Info

Year: 2025
Type: article
Volume: 14
Pages: 1-8
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Adjuvant abemaciclib in early-stage breast cancer: hypothesis-generating safety observations from a real-world cohort study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Federico Sottotetti, 
                                
                                    Simone Figini, 
                                
                                    Giulia Gambini
                                
                                et al.
                            
                            (2025). 
                            Adjuvant abemaciclib in early-stage breast cancer: hypothesis-generating safety observations from a real-world cohort study. 
                            Drugs in Context
                            , 14
                            
                            , 1-8.
                            https://doi.org/10.7573/dic.2025-7-5

Identifiers

DOI: 10.7573/dic.2025-7-5